Sanofi SA (SAN)
Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell
€91.75
Buy
€91.77
€1.90 (+2.11%)
Sanofi SA is healthcare company which is engaged in the research, development, manufacture and marketing of therapeutic solutions. It business activities include operations of specialty care, Established Prescription Products and vaccines operations.
Prices updated at 16 May 2025, 11:51 BST
| Prices minimum 15 mins delay
|
Prices in EUR
0.63%
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Drug Manufacturers - General
Chairman
Mr. Frederic Oudea
CEO
Mr. Paul Hudson
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
82,878
Head office
46, Avenue de la Great Army
Paris
France
75017
Key personnel
Owner name | Salary | Bonus | All other compensation | Total compensation | Restricted stock award |
---|---|---|---|---|---|
Mr. Francois-Xavier Roger Executive Vice President and Chief Financial Officer | - | - | - | - | - |
Ms. Lise Kingo Independent Director | 0.17m | - | - | 0.17m | - |
Mr. Olivier Charmeil Executive Vice President, General Medicines | - | - | - | - | - |
Mr. Paul Hudson Director and Chief Executive Officer | 1.30m | 4.23m | - | 5.53m | - |
Ms. Fabienne Lecorvaisier Independent Director | 0.17m | - | - | 0.17m | - |
Mr. Patrick Kron Independent Director | 0.20m | - | - | 0.20m | - |
Mr. Frederic Oudea Chairman of the Board | - | - | - | - | - |
Ms. Anne-Francoise Nesmes Independent Director | 0.12m | - | - | 0.12m | - |
Mr. Jean-Paul Kress Independent Director | - | - | - | - | - |
Mr. Christophe Babule Director | 0.16m | - | - | 0.16m | - |
Mr. John Sundy Independent Director | 0.11m | - | - | 0.11m | - |
Ms. Rachel Duan Independent Director | 0.15m | - | - | 0.15m | - |
Ms. Carole Ferrand Independent Director | 0.20m | - | - | 0.20m | - |
Dr. Antoine Yver, M.D.,M.Sc. Independent Director | 0.18m | - | - | 0.18m | - |
Ms. Natalie Bickford Executive Vice President and Chief People Officer | - | - | - | - | - |
Ms. Julie Van Ongevalle Executive Vice President, Consumer Healthcare | - | - | - | - | - |
Mr. Thomas Triomphe Executive Vice President, Vaccines | - | - | - | - | - |
Ms. Clotilde Delbos Independent Director | 0.12m | - | - | 0.12m | - |
Mr. Brendan O'Callaghan Executive Vice President, Global Manufacturing & Supply | - | - | - | - | - |
Mr. Roy Papatheodorou Executive Vice President and General Counsel | - | - | - | - | - |
Mr. Wolfgang Laux Director | 0.13m | - | - | 0.13m | - |
Ms. Barbara Lavernos Director | 0.16m | - | - | 0.16m | - |
Mr. Yann Tran Director | 0.11m | - | - | 0.11m | - |
Mr. Emile Voest Independent Director | 0.16m | - | - | 0.16m | - |
Ms. Madeleine Roach Executive Vice President, Business Operations | - | - | - | - | - |
Mr. Emmanuel Frenehard Executive Vice President and Chief Digital Officer | - | - | - | - | - |
Mr. Brian Foard Executive Vice President, Specialty Care | - | - | - | - | - |
Mr. Houman Ashrafian Executive Vice President and Head of Research and Development | - | - | - | - | - |
Ms. Audrey Duval Executive Vice President, Corporate Affairs | - | - | - | - | - |
Top 5 shareholders
Owner name | No. of shares | Share as % of port. | Last change | Portfolio % change | Date of portfolio | % Total assets |
---|---|---|---|---|---|---|
Capital Research and Management Company | 49,407,624 | 24.46577 | 7927824 | - | 30 Apr 2025 | 4.05 |
Vanguard Group Inc | 32,576,812 | 8.62527 | 547088 | - | 30 Apr 2025 | 2.67 |
BlackRock Fund Advisors | 22,482,050 | 35.38174 | 413798 | - | 30 Apr 2025 | 1.84 |
Dodge & Cox | 19,170,904 | 8.71028 | -227700 | - | 30 Apr 2025 | 1.57 |
Capital Group | 15,590,338 | 4.56839 | 3854243 | - | 30 Apr 2025 | 1.28 |
Director dealings
Date | Action | Name | Price | Value | No. of shares | Holding (%) | Additional info |
---|---|---|---|---|---|---|---|
No data |
Please note that past performance is not a reliable indicator of future returns.